公开(公告)号：US20230340086A1

公开(公告)日：2023-10-26

申请号：US17596652

申请日：2019-06-19

Applicant: Christopher Roland Oelkrug ,  Andreas Bernhard Joachim Schubert

Inventor： Christopher Roland Oelkrug ,  Andreas Bernhard Joachim Schubert

IPC: A61P31/04 ,  C07K16/12 ,  A61K45/06

CPC classification number: C07K16/1203 ,  A61K45/06 ,  A61P31/04 ,  A61K2039/55566

Abstract: Provided herein are antibodies, such as immunoglobulins Y (IgY) antibodies that inhibit beta-lactamase activity, e.g., TEM-1 beta-lactamase, as well as related compositions and methods of use thereof to treat infections by lactam-based antibiotic bacteria that produce beta-lactamase that can degrade antibiotics.

公开(公告)号：US20230338496A1

公开(公告)日：2023-10-26

申请号：US18178602

申请日：2023-03-06

Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

Inventor： Vincent BLASCO-BAQUE ,  Lucile GARIDOU ,  Remy BURCELIN

IPC: A61K39/02 ,  A61K39/114 ,  C07K16/12 ,  A61P1/02 ,  A61P3/10

CPC classification number: A61K39/0216 ,  A61K39/114 ,  C07K16/1203 ,  A61K39/0208 ,  A61P1/02 ,  A61P3/10 ,  A61K2039/522

Abstract: Vaccines for preventing or treating diabetes, obesity and complications thereof are provided. The vaccines comprise at least one active agent such as attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a cDNA from Porphyromonas gingivalis.

公开(公告)号：US20230266317A1

公开(公告)日：2023-08-24

申请号：US17641315

申请日：2020-09-09

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Michael CHAPLET ,  Nathalie NORAIS ,  Simona RONDINI ,  Silvia ROSSI PACCANI

IPC: G01N33/569 ,  C07K16/12

CPC classification number: G01N33/56911 ,  C07K16/1203 ,  G01N2333/212 ,  C07K2317/33

Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.

公开(公告)号：US20180256696A1

公开(公告)日：2018-09-13

申请号：US15761012

申请日：2016-09-23

Applicant: The Secretary of State for Health

Inventor： Julia Vipond ,  Kevin Bewley

IPC: A61K39/02 ,  C07K14/195 ,  C07K16/12 ,  G01N33/569 ,  A61K45/06

CPC classification number: A61K39/0208 ,  A61K45/06 ,  A61K2039/575 ,  C07K14/195 ,  C07K14/29 ,  C07K16/1203 ,  G01N33/56911

Abstract: The present invention provides antigens, for use in the treatment or prevention of C. burnetii infection. Also provided are nucleic acids encoding such antigens, and antibodies raised against such antigens.

公开(公告)号：US20180252709A1

公开(公告)日：2018-09-06

申请号：US15969493

申请日：2018-05-02

Applicant: DNAE Group Holdings Limited

Inventor： Sergey A. Dryga ,  Victor C. Esch ,  Lisa-Jo Ann Clarizia ,  Eddie W. Adams ,  Thearith H. Ung ,  Ravil A. Sitdikov

IPC: G01N33/543 ,  C07K16/12 ,  C12Q1/24 ,  G01N1/34 ,  G01N33/569 ,  C12N13/00

CPC classification number: G01N33/54333 ,  C07K16/1203 ,  C07K16/1267 ,  C07K2317/33 ,  C12N13/00 ,  C12Q1/24 ,  G01N1/34 ,  G01N33/569

Abstract: The invention generally relates to methods of using compositions that include sets of magnetic particles, members of each set being conjugated to an antibody specific for a pathogen, and magnets to isolate a pathogen from a body fluid sample.

公开(公告)号：US09988454B2

公开(公告)日：2018-06-05

申请号：US15159829

申请日：2016-05-20

Applicant: Immunwork Inc.

Inventor： Tse-Wen Chang ,  Hsing-Mao Chu ,  Chien-Jen Lin ,  Chun-Yu Lin

IPC: A61K47/48 ,  A61K31/137 ,  C07K16/10 ,  C07K16/12 ,  C07K16/18 ,  C07K16/28 ,  C07K17/06 ,  C07K14/565 ,  C07K7/08 ,  C07K14/00 ,  C07K17/02 ,  A61K47/65 ,  A61K47/60 ,  A61K47/64 ,  A61K47/68

CPC classification number: C07K16/283 ,  A61K31/137 ,  A61K47/60 ,  A61K47/64 ,  A61K47/65 ,  A61K47/6849 ,  A61K47/6883 ,  C07K7/08 ,  C07K14/001 ,  C07K14/565 ,  C07K16/1027 ,  C07K16/1203 ,  C07K16/18 ,  C07K16/2839 ,  C07K16/2881 ,  C07K17/02 ,  C07K17/06 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/70 ,  C07K2319/74

Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.

公开(公告)号：US20180105587A1

公开(公告)日：2018-04-19

申请号：US15851272

申请日：2017-12-21

Applicant: APO-T B.V.

Inventor： Johan Renes ,  Paulus J. Steverink ,  Ralph Alexander Willemsen

IPC: C07K16/18 ,  C07K16/12 ,  C07K16/28 ,  C07K16/10 ,  C07K16/08

CPC classification number: C07K16/18 ,  C07K16/082 ,  C07K16/087 ,  C07K16/10 ,  C07K16/1018 ,  C07K16/1045 ,  C07K16/1081 ,  C07K16/1203 ,  C07K16/1214 ,  C07K16/1217 ,  C07K16/1242 ,  C07K16/1271 ,  C07K16/1275 ,  C07K16/1292 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/55

Abstract: A first aspect of the disclosure relates to the field of binding molecules targeted at pathogens. The disclosure further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins.

公开(公告)号：US09938340B2

公开(公告)日：2018-04-10

申请号：US14877475

申请日：2015-10-07

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Herbert Andres ,  David Casagolda Vallribera ,  Hartmut Duefel ,  Michael Gerg ,  Christian Scholz ,  Michael Schraeml

IPC: C07K16/22 ,  C12N9/90 ,  C07K16/12 ,  G01N33/74 ,  C07K16/40 ,  G01N33/573 ,  C07K14/475 ,  C07K14/65

CPC classification number: C07K16/22 ,  C07K14/475 ,  C07K14/65 ,  C07K16/1203 ,  C07K16/40 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/23 ,  C07K2319/24 ,  C07K2319/35 ,  C07K2319/41 ,  C07K2319/43 ,  C12N9/90 ,  C12Y502/01008 ,  G01N33/573 ,  G01N33/74 ,  G01N2333/99

Abstract: Herein is reported a fusion polypeptide according to formula I NH2—S2—X1—S1—COOH  (formula I) wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and — denotes a peptide bond, wherein the second polypeptide is a polypeptide with peptidyl-prolyl cis/trans-isomerase activity (PPIase activity) or is derived from the FKBP-fold domain family, wherein X1 is inserted in place of the insert-in-flap-domain of the second polypeptide.

公开(公告)号：US09913904B2

公开(公告)日：2018-03-13

申请号：US15433497

申请日：2017-02-15

Applicant: MAT-MALTA ADVANCED TECHNOLOGIES LIMITED ,  FREISTAAT BAYERN REPRESENTED BY JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG

Inventor： Jan Wesjohann ,  Günter Sprotte ,  Ana Maria Waaga-Gasser

IPC: C07K16/02 ,  A61K39/40 ,  C07K16/12 ,  C07K16/14 ,  A61K39/00

CPC classification number: A61K39/40 ,  A61K2039/507 ,  C07K16/1203 ,  C07K16/1232 ,  C07K16/1235 ,  C07K16/1275 ,  C07K16/1282 ,  C07K16/14 ,  C07K2317/11 ,  C07K2317/23

Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.

公开(公告)号：US09815886B2

公开(公告)日：2017-11-14

申请号：US14592727

申请日：2015-01-08

Applicant: ADMA Biologics, Inc.

Inventor： Adam S. Grossman ,  James Mond ,  Jerrold B. Grossman ,  Dov A. Goldstein

IPC: A61K39/42 ,  C07K16/06 ,  A61K39/395 ,  C07K16/08 ,  C07K16/10 ,  A61K45/06 ,  G01N33/68 ,  C07K16/12 ,  A61K39/155 ,  A61K39/00

CPC classification number: C07K16/06 ,  A61K39/155 ,  A61K39/39516 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/507 ,  C07K16/08 ,  C07K16/10 ,  C07K16/1009 ,  C07K16/1027 ,  C07K16/1203 ,  C07K16/1232 ,  C07K16/1242 ,  C07K16/1271 ,  C07K16/1275 ,  C07K16/1282 ,  C07K16/1285 ,  C07K16/1289 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/76 ,  G01N33/6854 ,  Y02A50/466 ,  Y02A50/469

Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).